Avacta has developed three Affimer® proteins capable of binding to a recombinant form of a secreted Zika virus NS1 protein, the diagnostic of Zika virus infection at the early, acute stage.
These Affimer binders, with greater proven specificity than any available antibody, were identified and characterised within just 13 weeks, significantly faster than any other protein scaffold.
Enter your details above to download the Zika binders data pack
"Using Affimer technology, the data generated has been remarkable. My interest lies in understanding the mechanisms for blood clot formation and breakdown with the long-term aim of reducing heart attacks and strokes in high risk patients. A number of Affimer candidates have shown significant effects on the clotting process, which will help to develop novel therapeutic targets.”